The management of chronic diseases requires a constant monitoring of treatment adherence, in order to obtain an optimal disease control. However, this is often difficult to achieve, especially in pediatric age. In this sense, for asthmatic patients treated by Symbicort Turbohaler, "AstraZeneca" developed the "Turbo+", an electronic device attached to the Turbohaler, which allows to feel whether the patient does the inhalation, and to register it on a specific application. The present randomized trial aims to compare the treatment adherence between asthmatic children/adolescents aged 6-17 years treated with Symbicort Turbohaler plus Turbo+ or Symbicort Turbohaler without Turbo+.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council
Palermo, Sicily, Italy
Medication Adherence Rating Scale (MARS)
Change in the MARS score from baseline to the end of treatment
Time frame: 3 months
Childhood Asthma Control Test (C-ACT)
Change in the C-ACT score from baseline to the end of treatment
Time frame: 3 months
Asthma Control Test (ACT)
Change in the ACT score from baseline to the end of treatment
Time frame: 3 months
Pediatric Asthma Quality of Life Questionnaire (PAQLQ)
Change in the PAQLQ score from baseline to the end of treatment
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.